Join us at our Investors Day event showcasing pre-selected early-stage therapy developers in the cell and gene therapy space
The Cell and Gene Therapy Catapult are hosting this Investors Day event to bring together early-stage therapy developers and suitable investors to help accelerate their cell and gene therapy concepts toward patient benefit.
At this event, we'll start by showcasing Seed-level companies making progress towards a new investment round, followed by academics sharing their early-stage developments. All presenting groups have been pre-selected and have close ties with CGT Catapult.
Agenda:
12:45-1:15 - Registration
1.15-1.30pm – Welcome - Jonathan Appleby, Chief Scientific Officer, CGT Catapult
1.30-3.15pm - SESSION 1 – Talks from companies
- 1.30-1.45pm - VacV Biotherapeutics
- 1.45-2.00pm - Spliceor Therapeutics
- 2.00-2.15pm - Crucible Therapeutics
- 2.15-2.30pm - Rinri Therapeutics
- 2.30-2.45pm - Sania Therapeutics
- 2.45-3.00pm – Epilepsy GTx
- 3.00-3.15pm – Plurify
3.15-3.45pm – Break
3.45-5.00pm – SESSION 2 – Talks from academic groups
- 3.45-4.00pm - Dr Omer Dushek, University of Oxford
- 4.00-4.15pm - Dr Amin Hajitou, Imperial College London
- 4.15-4.30pm – Dr Richard Eva, King's College London
- 4.30-4.45pm – Dr Maike De La Roche, University of Cambridge
- 4.45-5.00pm – Dr Mark Isalan, Imperial College London
5.00-5.05pm – Closing remarks - Sam Goldsmith, Head of Commercialisation of Research and Investments, CGT Catapult
5.05-7.00pm - Drinks reception and networking
If you would like to learn more about our commercialisation of research activities, please contact sam.goldsmith@ct.catapult.org.uk